GreenCare, a Brazilian pharmaceutical manufacturer approved by Anvisa Marketing of three cannabis-based drugs in Brazil, It will start selling in pharmacies from August. Direct over-the-counter sales will make life easier for patients who are now forced to import drugs.
According to Martim Prado Mattos, CEO of GreenCare, “Exporting medication directly to each patient is a long process that must obtain Anvisa’s approval. and it takes 25 days from when the item is placed on the plane to delivery to Brazil”, the manager told the Estado de S. Paulo newspaper.
For which diseases are cannabis drugs indicated?
The three GreenCare drugs approved by Anvisa contain cannabidiol with different concentrations of THC, the principle that has a psychoactive effect in cannabis. Scientific studies have already shown that cannabis derivatives have positive applications in neurological, autoimmune, psychiatric diseases and chronic pain. Sales are subject to preliminary assessment and doctor’s prescription.
Although the drugs distributed by GreenCare are manufactured abroad, the company has acquired a former Merck factory in Vargem Grande Paulista (SP) and plans to manufacture them in Brazil. The manufacturer asked Anvisa to approve seven more drugs sold in pharmacies, three more by December and four more by 2023.
Source: Tec Mundo
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.
